A drug naive parkinsonian patient successfully treated with weak electromagnetic fields.

The International journal of neuroscience · 1994 · Benefit · Very low evidence

← Research stream

BenefitVery low evidencePaper 5448

A 49-year-old drug-naive Parkinson's disease patient reportedly showed marked improvement in motor symptoms, depressive symptomatology, and cognitive functions after brief extracranial applications of picotesla electromagnetic fields, with Hoehn and Yahr stag…

Study snapshot

PublicationThe International journal of neuroscience · 1994

Study typecase_report

Reported directionBenefit

Evidence ratingVery low

Abstract

Brief cerebral application of picotesla (pT) electromagnetic fields (EMF) has been demonstrated an efficacious, revolutionary treatment modality for the therapy of Parkinson's disease (PD) with clinical benefits being evident in all motor aspects of the disease as well as in nonmotor symptoms such as mood, sleep, pain, sexual dysfunction, autonomic regulation and cognitive functions. Since treatment with pT EMF has involved PD patients who were treated with dopaminergic agents at the time they received EMF there may have been a synergistic interaction between dopaminergic drugs and EMF. The present communication concerns a 49-year-old male Parkinsonian patient with stage 3 disability on the Hoehn and Yahr scale (1967) who, in response to brief extracranial applications of pT EMF, demonstrated a marked improvement in motor, depressive symptomatology and cognitive functions and was classified as stage 1 several weeks later. This case is remarkable in that the patient did not receive treatment with dopaminergic drugs prior to or during the course of EMF therapy. It suggests that (a) pT range EMF may be efficacious as a monotherapy for PD and should be considered also as a treatment modality for de novo diagnosed patients, and (b) application of these EMF improves Parkinsonism by a mechanism which involves, among others, augmentation of dopaminergic and serotonergic neurotransmission.

Machine Enhanced Logic

AI evidence extraction

Structured fields below were generated from the paper’s abstract and metadata to make the evidence easier to inspect. Automated extraction may be incomplete or incorrect; verify important details against the original paper.

Study typecase_report

Effect directionbenefit

Population49-year-old male patient with Parkinson's disease (Hoehn and Yahr stage 3 at baseline)

Sample size1

Exposurebrief applications; several weeks follow-up

Evidence strengthVery lowConfidence: 74% · Peer reviewed: yes

Main findings

Outcomes measured

Motor symptoms of Parkinson's disease
Depressive symptomatology/mood
Cognitive functions
Hoehn and Yahr stage

Limitations

Single-patient case report
No control/comparator described
Exposure parameters (e.g., frequency, dose) not specified in abstract
Follow-up duration only described as 'several weeks'
Mechanistic claims are speculative and not directly demonstrated in the case description

View raw extracted JSON

{
  "study_type": "case_report",
  "exposure": {
    "band": null,
    "source": "therapeutic extracranial/cerebral application of picotesla electromagnetic fields",
    "frequency_mhz": null,
    "sar_wkg": null,
    "duration": "brief applications; several weeks follow-up"
  },
  "population": "49-year-old male patient with Parkinson's disease (Hoehn and Yahr stage 3 at baseline)",
  "sample_size": 1,
  "outcomes": [
    "Motor symptoms of Parkinson's disease",
    "Depressive symptomatology/mood",
    "Cognitive functions",
    "Hoehn and Yahr stage"
  ],
  "main_findings": "A 49-year-old drug-naive Parkinson's disease patient reportedly showed marked improvement in motor symptoms, depressive symptomatology, and cognitive functions after brief extracranial applications of picotesla electromagnetic fields, with Hoehn and Yahr stage changing from 3 to 1 several weeks later.",
  "effect_direction": "benefit",
  "limitations": [
    "Single-patient case report",
    "No control/comparator described",
    "Exposure parameters (e.g., frequency, dose) not specified in abstract",
    "Follow-up duration only described as 'several weeks'",
    "Mechanistic claims are speculative and not directly demonstrated in the case description"
  ],
  "evidence_strength": "very_low",
  "confidence": 0.74,
  "peer_reviewed_likely": "yes",
  "keywords": [
    "Parkinson's disease",
    "picotesla electromagnetic fields",
    "extracranial application",
    "drug-naive",
    "motor symptoms",
    "depression",
    "cognition",
    "Hoehn and Yahr"
  ],
  "suggested_hubs": [
    {
      "slug": "therapeutic-emf",
      "weight": 0.78,
      "reason": "Reports clinical use of weak (picotesla) EMF as a treatment modality for Parkinson's disease."
    }
  ]
}

AI can be wrong. Always verify against the paper.

AI-extracted fields are generated from the abstract and metadata and may be incomplete or incorrect. This material is for informational purposes and is not medical advice.

Identifiers and source

DOI: 10.3109/00207459408986071
PubMed: 7744555

Read the original paper →

Related papers

← Back to the Research Library